Skip to main content

Lupus

259 SLE patients followed an 80% were in lupus low disease activity state (LLDAS); 82% in remission; 19% w/ active dz.

Dr. John Cush RheumNow ( View Tweet)

Oct 16, 2020

RheumNow Podcast – Good Time Charlie…. (10.16.20)

Oct 15, 2020

Dr. Jack Cush sings the news and journal reports from the past week on RheumNow.com.

Read Article
Observational study of 123 Spanish rheumatic dz pts w/ COVID-19, finds 54 hospitalized. Admitted pts were 69.7 yrs, and 22% died. Admission was assoc w/ older age, autoimmune dz (vs inflammatory arthritis; OR: 3.55), but not DMARD Rx. https://t.co/UWNyhOKbvF

Dr. John Cush RheumNow ( View Tweet)

Oct 13, 2020
The RheumNow Podcast is up - Bad Disease & Bad Outcomes. COVID consequences, TNFi Switching in SpA, psychosis in lupus?

Dr. John Cush RheumNow ( View Tweet)

Oct 11, 2020

RheumNow Podcast – Bad Disease & Bad Outcomes (10.9.20)

Oct 08, 2020

Dr. Jack Cush Reviews the news and journal articles from the past week on RheumNow.com.

Read Article
Lockdown worsening; UK survey 678 patients musculoskeletal diseases pts in late April 2020 shows 53% worsening of Sx; 1/3 had clinic/hosp access probs problems & most (88%) had no probs w/ getting meds; but 44% needed others to help them get meds.

Dr. John Cush RheumNow ( View Tweet)

Oct 07, 2020
Among 4766 mental health pts admited for Psychosis; 19% ANA tested and only 135 had a positive ANA >=1:160. (15% of those tested). Only 4 met 2019 ACR/EULAR criteria for SLE, and 2/4 met criteria for NPSLE. NPSLE prevalence was 1.5% in ANA+ psychosis Pts.

Dr. John Cush RheumNow ( View Tweet)

Oct 07, 2020
"Prednisone >30 mg/day for > 4 weeks, patients should be on PJP prophylaxis." Image shows when to start/stop PJP prophylaxis Dr. Kevin Winthrop on Risks/Prevention of OI @UTSWRheum Grand Rounds @rheumnow https://t.co/nXuWYRxbgy
Oct 05, 2020
RheumNow Podcast is up! COVID effects on Rheum; drug approvals, Difficult RA, SLE complement & remission.

Dr. John Cush RheumNow ( View Tweet)

Oct 02, 2020
Predictors of Remission in SLE? metanalysis of 17270 SLE pts; 42-88% achieved remission x 1 yr, & 21-70% for 5 yrs.

Dr. John Cush RheumNow ( View Tweet)

Oct 02, 2020

RheumNow Podcast – Function Follows Form (10.2.20)

Oct 01, 2020

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Regulatory approvals, update on global rheumatology alliance, smoking and psoriasis, gabapentin let down and defining difficult RA.

Read Article
Complement assoc. studied by Petri & Durcan in 2399 SLE pts. 55% had low C3 (pesistently low 4%); 47% low C4 (3% persistently low). Low C4 is weak marker clinical & serological Dz.

Dr. John Cush RheumNow ( View Tweet)

Oct 01, 2020

Slow Lung Decline Typical in Systemic Sclerosis

Sep 30, 2020

The interstitial lung disease that develops in a subset of patients with systemic sclerosis tends to be heterogeneous, with the majority of patients experiencing a slow pattern of decline in lung function, analysis of outcomes in the European Scleroderma Trials and Research (EUSTAR) database

Read Article

Novel Biologic Promising in Mid-Stage Scleroderma Trial

Sep 29, 2020

The anti-interleukin agent romilkimab showed significant benefits on skin fibrosis among patients with systemic sclerosis in a phase II trial, researchers reported.



At week 24, the least squares mean change from baseline on the modified Rodnan skin score was -4.76 for patients

Read Article

RheumNow Podcast – Cardiovascular Risk in Psoriatic Disease (9.25.20)

Sep 24, 2020

Dr. Jack Cush reviews the news and Journal articles from the past week on RheumNow.com.

Read Article

Romilkimab Effective in Early Diffuse Systemic Sclerosis

Sep 24, 2020

A phase II study of patients with early diffuse systemic sclerosis (SSc) has demonstrated improvement in SSc skin outcomes by targeting T cells and fibrosis with the bispecific monoclonal antibody romilkimab (RMK).



Romilkimab is an engineered, humanised, bispecific immunoglobulin-G4

Read Article
6.6% Risk of Late-onset Neutropenia (ANC<1000) in a single center study of 738 Rx w/ Rituximab (107 LON in 71 patients). Incidence was 7.2/100PYs. Higher risk w/ SLE or CTX Rx. 40% had Sxs, Fever 31%, sepsis in 8.5%.

Dr. John Cush RheumNow ( View Tweet)

Sep 21, 2020
The RheumNow podcast is up! Lupus delights - Lupus & Diet, Drug induced lupus & brand new biologics for SLE. Good news on immunosuppressives, colchicine and baricitinib in COVID-19 patients. .

Dr. John Cush RheumNow ( View Tweet)

Sep 18, 2020

RheumNow Podcast – Lupus Delights (9.18.20)

Sep 18, 2020

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com:

Read Article

COVID-19 Risks in Pregnant Women

Sep 17, 2020

There has been little science or evidence regarding the effects of COVID-19 infection on pregnancy and vice versa; and now the recent MMWR addresses the subject with two new reports

Read Article
Nurses' Health Study (79,568 women) examined the role of diet in 194 incident SLE cases and showed that diets (DASH, Meditteranean, antiinflammatory & healthy diets) had no significant effect of dietary quality on SLE risk https://t.co/JAFirjt0O8

Dr. John Cush RheumNow ( View Tweet)

Sep 17, 2020
NEJM report of 2 SLE pts treated w/ Daratumumab (anti-CD38) to deplete plasma cells a life-threatening refractory SLE.

Dr. John Cush RheumNow ( View Tweet)

Sep 17, 2020

Belimumab Effective in Lupus Nephritis

Sep 16, 2020

Dr. Rich Furie has lead a group of investIgators in reporting the significant efficacy of intravenous belimumab when added to standard of care induction therapy in patients with active lupus nephritis. This phase 3, 2-year study included 448 systemic lupus erythematosus patients with biopsy

Read Article
Taiwan National Health population study of 650 SLE and non-SLE controls undergoing hip replacement. SLE did not incr risk of early prosthetic infx, but did incr risk of late superficial wound infection (11.4% vs.

Dr. John Cush RheumNow ( View Tweet)

Sep 16, 2020

Mediterranean Diet May Reduce Risk of RA

Sep 15, 2020

Arthritis and Rheumatology reports that a Mediterranean diet (MD) is capable of reducing the high risk of RA among women who have smoked tobacco. The results stem from the E3N Study, a French prospective cohort study that collects dietary data on 98,995 women since 1990. An MD score was derived

Read Article
×